Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa RXC004 study
Redx Pharma Receives MHRA’s Positive Response for Restarting its P-I/IIa RXC004 study
Shots:
- Redx is working on study including lower starting dose and enhanced safety monitoring, assessing safety and tolerability of drug in patients with advance malignancies
- Redx claims that RXC004 a porcupine inhibitor belong to WNT signalling pathway, seems to be an attractive combination companion for immune-oncology agents
- Redx will finalize the suspended protocol for dosing of patients in H1’19
Click here to read full press release/ article | Ref: Redx Pharma | Image: Apconix